Immunovia will host a webcast with the opportunity to learn more about the positive clinical validation of the next generation pancreatic cancer test

Lund, Sweden, December 16, 2024 /PRNewswire/ — immunity (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, has published positive results in the clinical validation of a next-generation test for pancreatic cancer in… December 9, 2024. As a follow-up, immunity You will be hosting a webcast on Tuesday 17 December in 3pm CET.

Jeff BorcherdingCEO, Norma Alonzo PalmaPh.D., Clinical Vice President and medical (TASE:) affairs and Lisa Ford (NYSE:)Ph.D., the laboratory director will provide additional details about the study results and their implications. doctor. Amy LucasHead of the Department of Gastroenterology and Hepatology at Mount Sinai And a professor Medicine Icahn School of Medicinewill join the webcast to share views on the study results. The webcast will be held in English and will give attendees the opportunity to ask questions. You are invited to join, see details below.

Webcast link: https://link.edgepilot.com/s/e8dd2ee9/T5WEGMPm6EqzxajKwPwQbw?u=https://creo-live.creomediamanager.com/dd81645b-30e0-45e1-af83-75a059fcba71

A recording of the presentation will be available at Immunostaining Website.

For more information, please contact:
Karen Almqvist Lewendahl
CFO
karin.almqvist.liwendahl@immunovia.com

immunity short

Immunity AB It is a diagnostics company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. immunity It focuses on developing and marketing simple blood tests to detect proteins and antibodies that indicate that a person at high risk has developed pancreatic cancer.

immunity It collaborates and interacts with healthcare providers, leading experts, and patient advocacy groups to make its testing available to individuals at increased risk of developing pancreatic cancer.

USA It is the world's largest market for pancreatic cancer detection. The company estimates that at USAThere are 1.8 million individuals at risk of pancreatic cancer who could benefit from annual surveillance testing.

Immunostaining (IMMNOV) shares are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com

This information is brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-to-host-a-webcast-with-the-opportunity-to-learn-more-about-the-positive-clinical-validatio,c4082507

The following files are available for download: